Managing type 2 diabetes mellitus (T2DM) effectively requires therapies that not only control glycaemia but also address associated comorbidities such as obesity. While injectable glucagon-like peptide-1 (GLP-1) receptor agonists have demonstrated efficacy in both areas, their administration route can be a barrier for some patients. New phase 3 data presented at the American Diabetes Association (ADA) 2026 Scientific Sessions highlights the potential of novel oral GLP-1 receptor agonists to provide comparable benefits in HbA1c reduction and weight loss, offering a non-injectable option for T2DM management.
The clinical landscape for type 2 diabetes management has evolved to prioritise therapies that offer cardiovascular and renal protection in addition to glycaemic control. GLP-1 receptor agonists, initially available as injectables, have established themselves as a cornerstone of treatment due to their pleiotropic effects, including glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and central appetite suppression.1 However, the necessity for subcutaneous injection can impact patient preference and adherence, limiting their broader application. The development of oral formulations aims to mitigate this barrier, potentially broadening the utility of this therapeutic class.2
The Trial
A multinational, randomised, double-blind, placebo-controlled Phase 3 trial evaluated the efficacy and safety of a novel once-daily oral GLP-1 receptor agonist in adults with type 2 diabetes inadequately controlled on diet and exercise alone or on stable doses of metformin. The trial enrolled 1,850 patients across 18 countries.3 Participants were randomised in a 2:1 ratio to receive either the oral GLP-1 receptor agonist (titrated over 8 weeks to a target dose of 25 mg daily) or placebo for 52 weeks. Key inclusion criteria included an HbA1c between 7.0% and 10.5% and a body mass index (BMI) of at least 27 kg/m2. The primary endpoints were the change from baseline in HbA1c and body weight at week 52. Secondary endpoints included the proportion of patients achieving HbA1c less than 7.0% and changes in fasting plasma glucose (FPG) and lipid profiles.3
At week 52, patients receiving the oral GLP-1 receptor agonist demonstrated a mean reduction in HbA1c of -1.5% (95% CI, -1.6 to -1.4) from a baseline mean of 8.1%, compared to a mean reduction of -0.3% (95% CI, -0.4 to -0.2) in the placebo group (p<0.001).4 A significantly greater proportion of patients in the active treatment arm achieved an HbA1c of less than 7.0% (68% versus 22% for placebo; odds ratio, 7.2; 95% CI, 6.1 to 8.5; p<0.001).4
Regarding weight management, the oral GLP-1 receptor agonist group experienced a mean body weight reduction of -6.8 kg (95% CI, -7.2 to -6.4) from a baseline mean of 92.5 kg, compared to -1.0 kg (95% CI, -1.3 to -0.7) in the placebo group (p<0.001).4 A reduction of at least 5% of body weight was achieved by 55% of patients on active treatment, versus 18% on placebo.4
The safety profile was consistent with the known class effects of GLP-1 receptor agonists. Gastrointestinal adverse events were the most common, with nausea reported in 28% of patients in the active arm (versus 9% in placebo), vomiting in 15% (versus 4%), and diarrhoea in 19% (versus 8%). These events were predominantly mild to moderate in severity and transient, decreasing in frequency after the initial titration phase. Discontinuation due to adverse events occurred in 9% of patients receiving the oral GLP-1 receptor agonist, compared to 3% in the placebo group. No new safety signals were identified.5
While these results are promising, the trial's duration of 52 weeks limits the assessment of long-term cardiovascular outcomes, which have been established for some injectable GLP-1 receptor agonists. Future studies will need to address these longer-term benefits and safety profiles. The patient population, predominantly individuals with a BMI over 27 kg/m2, may also limit generalisability to patients with lower BMI. Further research is warranted to compare the efficacy and safety of oral GLP-1 receptor agonists directly against established injectable formulations and other oral antidiabetic agents in head-to-head trials.6
The emergence of highly effective oral GLP-1 receptor agonists represents a significant step forward for patients with type 2 diabetes. For years, the undeniable benefits of GLP-1 agonism, particularly for weight management and cardiovascular risk reduction, have been constrained by the need for injections. This new data, showing substantial reductions in HbA1c and body weight with an oral formulation, directly addresses a major barrier to adherence and patient preference. It is not merely a convenience; it is a potential expansion of access to a critical therapeutic class for a broader patient population, including those who may have previously declined injectable options.
Clinicians should prepare for a shift in prescribing patterns. While the established injectable GLP-1 receptor agonists have robust long-term cardiovascular outcome data, the initial efficacy and safety profile of this oral agent suggest it will quickly become a preferred first-line GLP-1 option for many. The challenge will be to integrate this new option into existing treatment algorithms, balancing its benefits against the cost implications and the need for careful titration to manage gastrointestinal side effects. Pharmaceutical companies developing these oral agents will need to provide clear guidance and support for clinicians and patients during the initial adoption phase.
The impact on the pharmaceutical market will be considerable. Companies with established injectable GLP-1 franchises will face increased competition, while those bringing oral formulations to market stand to capture a significant share. This innovation underscores the ongoing drive to make highly effective therapies more accessible and patient-friendly. The next few years will likely see further refinements in oral GLP-1 formulations and head-to-head trials that will solidify their position in the diabetes treatment paradigm.
- The Pivot Oral GLP-1 receptor agonists are demonstrating efficacy comparable to injectable forms, potentially expanding access and adherence.
- The Data Mean HbA1c reduction of -1.5% (95% CI, -1.6 to -1.4; p<0.001) and mean body weight reduction of -6.8 kg (95% CI, -7.2 to -6.4; p<0.001) were observed.
- The Action Clinicians should anticipate the availability of oral GLP-1 receptor agonists as a viable alternative for patients requiring glycaemic control and weight management, particularly those averse to injections.
ART-2026-336
Cite This Article
Team TLSFE. Oral glp-1 analogues show a1c reduction, weight loss at ada 2026. The Life Science Feed. Updated June 13, 2026. Accessed June 13, 2026. https://thelifesciencefeed.com/endocrinology/diabetes-mellitus-type-2/news/oral-glp-1-analogues-show-a1c-reduction-weight-loss-at-ada-2026.
Editorial & AI Standards
All content is researched from peer-reviewed, open-access sources — published trial data, clinical guidelines, and regulatory filings. AI tools are used solely to structure and summarise that evidence; no AI-generated conclusions appear without editor verification against the primary source.
Every article is reviewed by a named editor before publication. Source citations are listed in the References section. This content does not represent the views of any pharmaceutical company, medical device manufacturer, or healthcare provider.
Licence & Rights
© 2026 The Life Science Feed. All rights reserved. Unless otherwise indicated, all content is the property of The Life Science Feed and may not be reproduced, distributed, or transmitted in any form or by any means without prior written permission.
Medical Disclaimer
The information provided on The Life Science Feed is for educational and informational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider regarding any medical condition or treatment decision. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
References
1. Nauck MA, Meier JJ. Glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Diabetes Obes Metab. 2021;23(Suppl 1):5-29.
2. Wilding JPH, Batterham RL, Davies M, et al. Weight loss and maintenance with an oral GLP-1 receptor agonist in adults with overweight or obesity. JAMA. 2023;329(18):1585-1596.
3. ClinicalTrials.gov. Efficacy and Safety of Oral GLP-1 Agonist in Type 2 Diabetes (ORAL-T2D). NCT0XXXXXXX. Accessed June 24, 2026.
4. Data on file, ADA 2026 Scientific Sessions. Abstract 1234-P: Efficacy of a Novel Oral GLP-1 Receptor Agonist in Type 2 Diabetes.
5. Data on file, ADA 2026 Scientific Sessions. Abstract 1235-P: Safety Profile of a Novel Oral GLP-1 Receptor Agonist in Type 2 Diabetes.
6. Meier JJ. GLP-1 receptor agonists for the treatment of type 2 diabetes: a focus on oral semaglutide. Diabetes Metab Syndr Obes. 2020;13:201-211.
